Safety and Efficacy of Immune Therapy for Condyloma
- Conditions
- Condylomata Acuminata
- Interventions
- Biological: DC-CIK immunotherapy
- Registration Number
- NCT03158480
- Lead Sponsor
- Shenzhen Second People's Hospital
- Brief Summary
Cytokine-induced killer (CIK) cells will be co-cultured with HPV induced dendritic cells (DCs); HPV specific DC-CIK will be induced to Condylomata Acuminata patients using interferon, whose recurrence rate and total cost will be compared to Condylomata Acuminata patients only use interferon.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 80
All patients have typical clinical characters of condyloma, positive for HPV-DNA test; All patients have been treated for cryotherapy or laser plus interferon for over half a year without completely recovery. All patients or their family will sign informed consent and approved by Ethics Committee of Shenzhen Second People's Hospital -
pregnant, blood disease, contraindication for immune therapy, allergic to interferon
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo+interferon Group DC-CIK immunotherapy saline as placebo plus interferon intervention DC-CIK+interferon Group DC-CIK immunotherapy dendritic cell-activated cytokine-induced killer cells (DC-CIK) immunotherapy plus interferon intervention
- Primary Outcome Measures
Name Time Method Condylomata Acuminata recurrence rate 6 months Condylomata Acuminata recurrence rate in 6 months after treatment
- Secondary Outcome Measures
Name Time Method side effect 6 months evaluate and record side effect of each group
skin tissue HPV gene 6 months use PCR to testify skin tissue HPV gene
Trial Locations
- Locations (1)
Shenzhen Second Hospital
🇨🇳Shenzhen, Guangdong, China